Highlights from ASH 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

Perspectives on molecular monitoring in CML from 
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia

• Treatment-free remission studies including an update of the EURO-SKI trial
• New data on optimal timing for monitoring patients after stopping therapy
• Additional chromosomal abnormalities and their impact on prognosis
• Next generation sequencing technologies 

 {rscomments off}